CERE
Barclays’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-50,865
| Closed | -$2.08M | – | 4527 |
|
|
2024
Q2 | $2.08M | Sell |
50,865
-43,083
| -46% | -$1.76M | ﹤0.01% | 1674 |
|
|
2024
Q1 | $3.97M | Sell |
93,948
-258,414
| -73% | -$10.9M | ﹤0.01% | 1499 |
|
|
2023
Q4 | $14.9M | Buy |
352,362
+206,452
| +141% | +$8.75M | 0.01% | 840 |
|
|
2023
Q3 | $3.19M | Buy |
145,910
+14,568
| +11% | +$318K | ﹤0.01% | 1394 |
|
|
2023
Q2 | $4.18M | Sell |
131,342
-469,712
| -78% | -$14.9M | ﹤0.01% | 1320 |
|
|
2023
Q1 | $14.7M | Buy |
601,054
+144,439
| +32% | +$3.52M | 0.01% | 687 |
|
|
2022
Q4 | $14.4M | Buy |
456,615
+358,880
| +367% | +$11.3M | 0.01% | 728 |
|
|
2022
Q3 | $2.76M | Buy |
97,735
+94,920
| +3,372% | +$2.68M | ﹤0.01% | 1438 |
|
|
2022
Q2 | $74K | Sell |
2,815
-4,002
| -59% | -$105K | ﹤0.01% | 3591 |
|
|
2022
Q1 | $239K | Buy |
+6,817
| New | +$239K | ﹤0.01% | 3207 |
|